唑来膦酸治疗恶性肿瘤骨转移疼痛的临床研究

目的:观察唑来膦酸治疗恶性肿瘤骨转移疼痛的疗效和安全性。方法:53例患者随机分为治疗组和对照组,治疗组(26例)采用唑来膦酸4mg加入生理盐水50mL静脉滴注15min以上;对照组(27例)采用帕米膦酸二钠90mg加入生理盐水500mL静脉滴注6h,两组均一次性给药后观察28d。结果:治疗组和对照组总有效率分别为65.38%和62.65%,疗效无显著性差异,P>0.05;不良反应主要为发热、头痛、恶心呕吐、乏力等,均较轻微。结论:唑来膦酸是新一代骨吸收抑制剂,对恶性肿瘤骨转移所致疼痛有较好的临床疗效,不良反应较少,具有使用更方便的优势。

The Clinical Study of Zoledronic Acid in Treating Metastatic Bone Pain of Malignancy

Objective:To investigate the effect and safety of zoledronic acid in the treatment of pain caused by malignant tumor osseous metastasis. Methods:53 cases were randomly into two groups. The experimental group (26 cases) was treated intravenously by 4 mg zoledronic acid for 15 minutes on the first day; the control group (27 cases) was treated intravenously by 90 mg pamidronate for 6 hours. The patients were followed up for 28 days to assess the efficacy and safety. Results:The response rate of zoledronic acid and pamidronate was 65.38% and 62.65%,respectively. The total response rate between the two groups was no statistical difference. The main side effects were fever. headache, nausea, vomiting, and debilitation, no severe adverse events were found. Conclusion:Zoledronic acid is effective and safe in the treatment of patient with metastatic bone pain of malignancy.